Cancer drug protein target may also help fight influenza

A protein already targeted by FDA-approved cancer drugs may also help the body fight influenza, according to new research from The Jackson Laboratory (JAX). Published in Cell Reports, the study found ...
The Lancet

PD-L1, treatment intensity, and outcomes in squamous NSCLC

We read with interest the results of the HARMONi-6 trial by Zhiwei Chen and colleagues,1 which showed that ivonescimab plus chemotherapy improved progression-free survival versus tislelizumab plus ...
Labroots

Known Cancer Target Helps Fight Influenza

Drugs and different treatments approved by the U.S. Food and Drug Administration (FDA) for a specific disease can be repurposed for other pathologies. The | Immunology ...
Cure Today

PD-L1, KIM-1 Levels May Predict Kidney Cancer Response to Opdivo, Yervoy

PD-L1 expression predicts better outcomes with nivolumab and ipilimumab in ccRCC, aligning with previous trial results. High KIM-1 expression is linked to worse DFS, suggesting its potential as a ...
EurekAlert!

Gut microbes rewrite the rules of cancer immunotherapy

Cancer immunotherapy has transformed oncology, yet many patients fail to respond or eventually develop resistance.
Business Wire

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that in a recent meeting the U.S. Food and Drug Administration (FDA) concurred with the Company’s approach to ...
Business Wire

FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 ...

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced the potential positive impact on the clinical development of its immunotherapy Multikine® (Leukocyte Interleukin, ...